MSD Korea launches novel carbapenem antibiotic
Published: 2004-02-09 06:59:00
Updated: 2004-02-09 06:59:00
MSD Korea, a Korean business unit of a multinational pharmaceutical firm, said it launched Invanz injection (ertapenem sodium), a novel carbapenem antibiotic for the treatment of complicated intra-abdominal infections and complicated skin/skin structure infections.
Ertapenem sodium inhibits th...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
